TNF and inflammatory bowel disease: We hypothesized that those on anti-TNF therapy would continue to demonstrate higher CMIR compared with patients with IBD on other treatments, as we have previously seen in our HumoRal and CellULar initial and Sustained immunogenicity in patients with IBD (HERCULES) cohort.